Meet Dr. Giuseppina Tesco, Cure Alzheimer’s Funded researcher, and assistant professor of neuroscience, Alzheimer’s Disease Research Laboratory, Department of Neuroscience, Tufts University School of Medicine.
A Pittsburgh philanthropist and retired Mellon exec thinks so. In 1988, Jeffrey L. Morby left American Express to join the management team tapped to rescue the nearly bankrupt Mellon Bank. After helping turn Mellon around, he retired at 59, but Morby has hardly been wiling away the time.
When Maggie Campbell’s mother-in-law, Nancy Drapeau, was diagnosed with early-onset Alzheimer’s disease last summer at age 59, Campbell decided she wanted to do something to help. Originally from Omaha, Neb., Campbell is a bookbinder and letterpress printer in Brooklyn, N.Y.
From our 2011 Annual Report.
On behalf of the Board of Directors and the Research Consortium, we want to thank all the donors, researchers and academic institutional partners supporting Cure Alzheimer’s Fund research for your help in making 2011 such a successful science year. Guided by leading scientists in the field, Cure Alzheimer’s Fund-supported research continues to make breakthrough progress toward our goal of eradicating Alzheimer’s disease.
Rudy Tanzi, Chair, Cure Alzheimer's Fund Research Consortium comments here on the AP article appearing on this topic today:
Alzheimer’s is the sixth leading cause of death in the United States, but its most devastating effects can’t be counted. The disease steals away memories; it turns loved ones into strangers; it makes home unfamiliar and takes away all the things that define an individual. And, until recently, there’s been little hope of stopping its progress.
Cure Alzheimer’s Fund was founded to support cutting-edge, high-potential research to help the Alzheimer’s research community get on a smarter, faster trajectory toward a cure.
Consensus among Alzheimer’s researchers about the origins of the disease is growing. Most, including members of Cure Alzheimer’s Fund Research Consortium, agree that a combination of factors, beginning with the excessive build-up of the peptide Abeta42 triggering the development of tau tangles, nerve cell death, and inflammation are all required for Alzheimer’s pathology.
(October 29, 2012) (PRWEB) October 30, 2012 -- The Brain Research Foundation (BRF) today announced that the 2012 recipients of the Frederic A. Gibbs Discovery Award will be Michael W. Ferro Jr. and David M. Holtzman, M.D.
Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development
Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer’s Whole Genome Sequencing (WGS) focused on families afflicted with the disease.
© 2005-2016 Cure Alzheimer's Fund. All rights reserved.